Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency-Reference-Cited by-同舟云学术

Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency

Published:2022-12-23 Issue:2 Volume:20 Page:1247-1255
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Ko Sanghwan¹²,Ju Man-Seok¹²,Ahn Hye-Mi³,Na Jung-Hyun⁴^ORCID,Ko Woo Hyung¹⁵,Jo Migyeong¹⁵,Kyung Munsu¹⁵,Lim Chung Su⁶,Ko Byoung Joon⁷,Lee Won-Kyu⁶^ORCID,Kim Youn-Jae³,Jung Sang Taek¹²⁵^ORCID

Affiliation:

1. Department of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Republic of Korea

2. Institute of Human Genetics, Korea University College of Medicine, Seoul 02841, Republic of Korea

3. Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Gyeonggi-do 10408, Republic of Korea

4. Department of Pharmaceutical Engineering, Sangji University, Wonju, Gangwon-do 26339, Republic of Korea

5. BK21 Graduate Program, Department of Biomedical Sciences, Korea University College of Medicine, Seoul 02841, Republic of Korea

6. New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, Chungcheongbuk-do 28160, Republic of Korea

7. School of Biopharmaceutical and Medical Sciences, Sungshin Women’s University, Seoul 02844, Republic of Korea

Funder

National Cancer Center

National Research Foundation of Korea

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00923

Reference42 articles.

1. Engineering therapeutic antibodies targeting G-protein–coupled receptors

2. A human antibody against human endothelin receptor type A that exhibits antitumor potency

3. Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies

4. Conducting the G-protein coupled receptor (GPCR) signaling symphony in cardiovascular diseases: New therapeutic approaches

5. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer